Boothbay Fund Management’s BridgeBio Pharma BBIO Stock Holding History

Boothbay Fund Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.26M	Buy	+17,000	New	+$1.23M	0.02%	825
2025 Q2	–	Sell	-192,600	Closed	-$6.66M	–	1454
2025 Q1	$6.66M	Sell	192,600 -10,500	-5%	-$354K	0.18%	157
2024 Q4	$5.57M	Buy	+203,100	New	+$5.25M	0.14%	217
2024 Q3	–	Sell	-174,700	Closed	-$4.43M	–	1623
2024 Q2	$4.43M	Buy	174,700 +65,400	+60%	+$1.79M	0.1%	264
2024 Q1	$3.38M	Buy	+109,300	New	+$3.72M	0.07%	337
2023 Q4	–	Sell	-62,400	Closed	-$1.65M	–	1654
2023 Q3	$1.65M	Sell	62,400 -187,900	-75%	-$5.33M	0.04%	569
2023 Q2	$4.31M	Sell	250,300 -4,600	-2%	-$69.2K	0.09%	260
2023 Q1	$4.23M	Buy	+254,900	New	+$2.97M	0.09%	311
2022 Q3	–	Sell	-25,500	Closed	-$232K	–	2243
2022 Q2	$232K	Buy	+25,500	New	+$213K	0.01%	1636
2022 Q1	–	Sell	-28,200	Closed	-$470K	–	2269
2021 Q4	$470K	Buy	+28,200	New	+$1.19M	0.01%	1042

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's BBIO Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 46,981 shares worth $3.49M. The stake represents 0.05% of the portfolio and ranks #419 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in BBIO as recently as Q3 2025.

Boothbay Fund Management first reported a position in BBIO in Q4 2021 and has held it in 12 quarters since. The position peaked at $4.21M in Q4 2023. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Boothbay Fund Management held 46,981 shares of BridgeBio Pharma worth $3.49M as of Q1 2026.
BridgeBio Pharma was a new Boothbay Fund Management position in Q1 2026.
BridgeBio Pharma made up 0.05% of Boothbay Fund Management's portfolio in Q1 2026, its #419 holding.
Boothbay Fund Management first reported a position in BridgeBio Pharma in Q4 2021 and has held it in 12 quarters since.
Boothbay Fund Management's BridgeBio Pharma position peaked at $4.21M in Q4 2023.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.